Publications by authors named "A V Spivak"
Article Synopsis
- Tidal wetlands can absorb greenhouse gases, but methane emissions can vary due to environmental factors and human activities.
- Land managers require detailed maps of methane properties in these wetlands for effective restoration and greenhouse gas inventories, yet current sampling methods don't align well with broader mapping products.
- Research involved sampling 27 tidal wetlands, revealing that sulfate concentration is the strongest predictor of methane levels, while salinity also plays a significant role; future studies should focus on understanding local environmental influences on methane variation.
Introduction: Patients with multiple sclerosis and Parkinson's disease may experience pelvic floor dysfunction and constipation which can affect ileoanal pouch emptying. This can lead to complications such as pouchitis, pouch dysfunction, and failure. We hypothesized that patients with neurological diseases have a higher rate of pouch failure and complications than healthy controls.
View Article and Find Full Text PDFSustained antiviral response against HIV-1 infection in peripheral blood mononuclear cells from people with chronic myeloid leukemia treated with ponatinib.
Mario Manzanares Fernando Ramos-Martín Sara Rodríguez-Mora Guiomar Casado-Fernández Clara Sánchez-Menéndez Adam M Spivak
Front Pharmacol
September 2024
Article Synopsis
- - HIV-1 infection persists due to long-term viral reservoirs in latently infected CD4 T cells, prompting the need for strategies to stimulate cytotoxic immunity, including the "Shock and Kill" approach.
- - Ponatinib, a tyrosine kinase inhibitor used for chronic myeloid leukemia, has shown effectiveness against HIV-1 and may enhance the immune response against both cancer and viral infections.
- - In a study of patients with chronic myeloid leukemia who switched from imatinib to ponatinib, results indicated that ponatinib treatment significantly reduced HIV-1 infection rates and increased the cytotoxic response from peripheral blood mononuclear cells, with effects lasting at least 12 months post-treatment.